Stocktoria
Celcuity Inc. CELC
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2017-09-20
Celcuity Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $145.0M | $104.2M | $60.6M | $35.3M | $25.8M |
| Operating income | -$172.2M | -$113.3M | -$66.2M | -$39.4M | -$28.4M |
| Interest expense | — | — | $5.3M | $2.1M | $1.3M |
| Net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | -$29.6M |
| EPS (diluted) | $-3.79 | $-2.83 | $-2.69 | $-2.64 | — |
| Operating cash flow | -$153.3M | -$83.5M | -$53.8M | -$36.0M | -$20.3M |
| Free cash flow | -$153.5M | -$83.7M | -$53.9M | -$36.2M | -$20.4M |
| Cash & equivalents | $165.7M | $22.5M | $30.7M | $24.6M | $84.3M |
| Total assets | $466.6M | $245.1M | $191.2M | $175.7M | $85.9M |
| Total liabilities | $366.0M | $129.5M | $51.5M | $41.9M | $17.2M |
| Shareholders' equity | $100.6M | $115.6M | $139.8M | $133.8M | $68.7M |
Source: SEC EDGAR filings · CIK 0001603454 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.